Appointment dossier — Pancreatic Cancer
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Pancreatic Cancer
- Fuzuloparib — Review evidence · 1 positive · PMID 34118019
- Relacorilant — Review evidence · 1 positive · PMID 42334771
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT06757244 · Phase 2 — DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer (France)
- NCT07504471 · Phase 2 — Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhibitors for Pancreatic Cancer Liver Metastases (China)
- NCT07600268 · Phase 2 — Efficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Maintenance Therapy Compared to Maintenance Therapy Alone in Advanced Pancreatic Cancer (China)
- NCT05679583 · Phase 2 — Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer (South Korea)
- NCT06387342 · Phase 2 — Namodenoson Treatment of Advanced Pancreatic Cancer (Israel)
- NCT06816823 · Phase 1 — CAR-NK Cells (CL-NK-001) in Pancreatic Cancer (China)
- NCT06454383 · Phase 1 — Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer (United States)
- NCT05740956 · Phase 1 — A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors (China)
- NCT03823144 — Intravital Microscopy in Human Solid Tumors (United States)
- NCT06937996 — Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation System- (United States)
- NCT03551951 — Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow (United States)
- NCT04291651 — UCSF PANC Cyst Registry (United States)
- NCT06914128 · Phase 1 / Phase 2 — A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors (United States)
- NCT05288205 · Phase 1 / Phase 2 — Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation (China)
- NCT03093688 · Phase 1 / Phase 2 — Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor (China)
- NCT07165132 · Phase 1 — Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs. (United States)
- NCT07458347 · Phase 1 — A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation (United States)
- NCT04990609 · Phase 2 — EUS-RFA PANCARDINAL-1 Trial (United States)
Most-relevant first: trials that name Pancreatic Cancer, then broader trials you may still qualify for. 896 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.
Questions to ask your oncologist
- Of the open trials I found (for example NCT06757244), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?
- Should my tumor tissue be stored (biobanked) for future testing or trials?